Bolt Biotherapeutics, Inc. (BOLT) company profile
Close on Nov 13, 2026Market cap $11.71MP/E –Yield –
About Bolt Biotherapeutics
Pharmaceutical Preparations, SIC 2834
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on developing cancer treatments by engaging the innate immune system. Utilizing its proprietary Boltbody Immune-Stimulating Antibody Conjugate platform, the company combines tumor-targeting antibodies with immune-stimulating linker-payloads to generate anti-tumor immune responses. Its lead clinical product candidate, BDC-4182, targets claudin 18.2 for the treatment of gastric and gastroesophageal junction cancers. Additionally, its pipeline includes preclinical programs such as a CEA-targeted ISAC, a PD-L1-targeted ISAC, and BDC-3042, an agonist antibody targeting dectin-2 to repolarize tumor-associated macrophages. The company operates in the biopharmaceutical research and development space, engaging with industry partners and academic institutions.
The company conducts its corporate, clinical, and research activities within the United States. Its primary executive offices and laboratory facilities are situated in Redwood City, California. Bolt Biotherapeutics operates without internal commercial manufacturing facilities, instead relying on third-party contract development and manufacturing organizations for clinical product supplies.
Summary of the business section of Bolt Biotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bolt Biotherapeutics, Inc.
- Founded
- 2015
- Headquarters
- Redwood City, CA
- Address
- 900 Chesapeake Drive 94063
- Phone
- (650) 665-9295
- Website
- boltbio.com
- Employees
- 23, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- BOLT
- Exchange
- Nasdaq
- IPO date
- Feb 5, 2021
- Shares outstanding
- 2M, Aug 4, 2026
- Public float
- $7.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Jun 9, 2025
- SEC CIK
- 1641281
- CUSIP
- 097702203
- ISIN
- US0977022039
- FIGI
- BBG00N8MY5V9
- Share class FIGI
- BBG00N8MY5W8
- LEI
- 254900W0P77PQ6B8OY50
- EIN
- 47-2804636
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sheila Gujrathi | Chief Strategy Officer, Director | 85,821 |
| William P. Quinn | President, CEO and CFO, Director | 25,384 |
| Grant Yonehiro | Chief Operating Officer | 17,269 |
| Sarah Nemec | Senior VP, Finance and PAO | 17,082 |
| Nicole Onetto | Director | 0 |
| Laura Berner | Director | 0 |
| Kathleen Laporte | Director | 1,200 |
| Jakob Dupont | Director | – |
| Brian O'Callaghan | Director | 0 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| William P. Quinn President, Chief Executive Officer and Chief Financial Officer | $463.50K | $191.20K | $224.40K | $3.67M | $10.50K | $4.56M | +279% |
| Grant Yonehiro Chief Operating Officer | $463.50K | $139.10K | $168.30K | $3.24M | – | $4.01M | +323% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 5, 2021
- Offer price
- $20.00
- Securities offered
- 11,500,000
- Gross proceeds
- $230.00M
- Exchange
- Nasdaq
- First trading day
- Feb 5, 2021
- First-day close
- $32.15+60.7%
- Lock-up ends (est.)
- Aug 4, 2021
“The initial public offering price is $20.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 23 employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 23, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 6, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 3, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 3, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 14, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 5, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 2, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 7, 2015 | Name change | Name changed from Bolt Therapeutics, Inc. to Bolt Biotherapeutics, Inc. |
See a number that looks wrong?